Ostirein

Quick links to important sections

Ostirein

Method of action: Anti-Inflammatory, Antirheumatic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ostirein

Property Description
Active Ingredient Diacerein (INN)
Form Hard capsule
Pharmacological Class Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA)
Common Use Targeting structural issues in degenerative joint conditions
Origin Semi-synthetic anthraquinone derivative

What Type of Medicine is Ostirein? (Classification and Form)

Ostirein is the proprietary name for a medicine containing the active substance Diacerein (INN), which is classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA). This designation indicates a therapeutic approach focused on modifying the structural aspects of degenerative joint disease. The medicine is administered via the oral route and is typically formulated as a hard capsule. Its classification is formally recognized by the Anatomical Therapeutic Chemical (ATC) code M01AX21, which places it within the group of non-steroidal anti-inflammatory and anti-rheumatic products. Diacerein is a unique SYSADOA whose benefits in modulating joint destruction have been clinically recognized by European guidelines. This confirms that the medicine is used for its action on the disease process rather than just immediate pain relief, making it distinct from common analgesics.


Composition and Origin of the Active Ingredient (Diacerein)

The active substance, Diacerein, is a semi-synthetic anthraquinone derivative, chemically belonging to the anthraquinone family. It functions as an orally administered prodrug, meaning it is pharmacologically inactive upon ingestion and must be metabolized by the body into its potent active compound, Rhein, to exert its therapeutic effect. This requirement for biotransformation explains the medicine's characteristic slow-acting nature. The final pharmaceutical product is a single active ingredient formulation, relying solely on Diacerein for its primary therapeutic role.


General Therapeutic Role and Purpose

The general therapeutic purpose of this medication is to mitigate the progression of damage associated with degenerative joint conditions by intervening in the biochemical processes that drive cartilage breakdown. As a slow-acting agent and a SYSADOA, its role is not to provide immediate symptom relief, but rather to serve a foundational function by stabilizing the joint environment. By reducing the destructive influence of key inflammatory signaling proteins, Diacerein aims to modify the long-term structural course of the condition, offering a distinct approach compared to medicines that only treat acute pain. It is typically considered for use in adults experiencing long-term discomfort and stiffness associated with wear and tear in major joints.

Regulatory References

  1. EMA Article 31 referral for Diacerein

What side effects are possible with Ostirein?

Possible Side Effects and Safety Information

Ostirein, which contains the active substance Diacerein, has an officially documented safety profile primarily characterized by effects on the gastrointestinal and hepatobiliary systems, as classified by regulatory authorities.


Frequency and System-Organ Classes

The most frequent adverse reactions are classified as Very Common (may affect more than 1 in 10 individuals) and include diarrhoea and abdominal pain. These effects are often most noticeable during the initial stages of treatment and are generally documented to lessen with continued use.

Reactions categorized as Common (may affect up to 1 in 10 individuals) include frequent bowel movements, flatulence, and effects on the Skin and Subcutaneous Tissue Disorders system such as pruritus (itching), rash, and eczema. Uncommon effects include cases of elevated hepatic enzymes in serum.


Serious Safety Concerns and Restrictions

Official labeling highlights the risk of serious reactions. Acute liver injury and hepatitis, including fatal outcomes, have been reported in post-marketing surveillance, with most cases occurring during the first months of treatment. Severe diarrhoea, which may lead to dehydration and disturbances in fluid and electrolyte balance, is also documented as a serious concern.

Regulatory restrictions define the use of Ostirein in specific populations:

  • Hepatic Impairment: The medicine is contraindicated (must not be used) in individuals with a diagnosis of, or a history of, liver disease.
  • Older Adults: Use is not recommended for patients aged 65 years and above due to the risks associated with severe diarrhoea and its complications.

Caution is also documented when the medicine is used alongside agents like diuretics due to the increased potential for dehydration and low potassium levels (hypokalaemia) secondary to diarrhoea. The active metabolite may also cause a harmless darker coloration of urine.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

An overdose of Ostirein, which contains Diacerein, is officially characterized by the over-manifestation of its known gastrointestinal effects. The documented primary clinical sign following an acute overdose is profuse diarrhea. This severe symptom carries a serious physiological risk, as it can rapidly lead to dehydration and critical electrolyte disorders, most notably hypokalaemia.

The official regulatory documents mandate specific actions in an overdose scenario. Immediate medical attention must be sought if symptoms are suggestive of acute hepatic injury (such as jaundice or abdominal pain) are present. Furthermore, if severe diarrhea occurs, a physician must be contacted immediately. Symptomatic treatment is required, focusing on correcting the resulting dehydration and electrolyte imbalances.

No specific antidote is formally documented in the official prescribing information. Close supervision is advised for patients older than 65 years, and a heightened risk of cardiac arrhythmia due to hypokalaemia exists in patients concurrently taking diuretics or cardiac glycosides. The regulatory profile emphasizes that management centers entirely on supportive care and monitoring for severe complications.

Therapeutic Uses of Ostirein

The medication is commonly used to help with the symptomatic treatment of degenerative joint disease. It is relevant in contexts marked by increased discomfort and is applied in addressing symptom clusters that may become intense or disruptive, such as chronic joint pain and stiffness.

Ostirein plays a foundational role in the long-term management of symptomatic OA, particularly when the condition affects major weight-bearing joints like the knee and hip. It is considered appropriate for patients seeking support where additional symptomatic support is needed, with benefits that include helping to maintain a sense of stability when symptoms are more noticeable, and contributing to improved day-to-day comfort.

This treatment is relevant in contexts involving heightened systemic burden, and may assist with managing symptoms that interfere with daily comfort. The support provided may continue to contribute to easing the overall symptom load after the administration period. This medication is relevant in clinical settings that involve acute or unstable symptom patterns, offering supportive relief.

Quick Fact: Management of Long-Term Joint Discomfort
Ostirein is relevant in situations involving recurrent or episodic manifestations, and helps to ease the overall symptom burden by managing chronic pain and stiffness associated with established osteoarthritis.

Eligibility and Restrictions for Use

Who can and cannot use Ostirein?

Ostirein (Diacerein) is approved for use in adults typically between 18 and 64 years old for the symptomatic treatment of osteoarthritis of the hip or knee. Eligibility is strictly defined by regulatory guidelines that mandate specific exclusions and strong use restrictions.

Absolute Contraindications

The medicine is contraindicated and must not be used by any patient with a current or history of liver disease. Use is also prohibited in patients with a known hypersensitivity to the active substance or its derivatives, and those with inflammatory organic bowel disease.

Populations Not Recommended or Restricted

Use is generally not recommended for patients aged 65 years and above due to the increased risk of complications. Ostirein is also not recommended for patients with rapidly progressive hip osteoarthritis.

For specific physiological states, use is not recommended during pregnancy or while breastfeeding. Treatment must be stopped immediately if the patient develops diarrhea.

Patients with severe renal insufficiency are eligible for use only if the standard daily dosage is halved. Use in children and adolescents (under 18) is not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ostirein (Diacerein) has documented interaction patterns that require specific administration timing or caution due to altered drug exposure and additive physiological risks, as specified in regulatory labeling.


Documented Interaction Patterns

Substance / Product Interaction Type Official Restriction / Condition
Antacids (Aluminum, Magnesium, Calcium) Pharmacokinetic (Reduced Absorption) Must be administered at least two hours apart from Ostirein to avoid significantly decreasing Diacerein's systemic exposure.
Diuretics (Loop and Thiazides) Pharmacodynamic (Additive Risk) Requires caution; Diacerein-induced loose stools can cause hypokalemia, increasing the risk of cardiac events when combined with these medicines.
Cardiac Glycosides (e.g., Digoxin) Pharmacodynamic (Additive Risk) Requires caution; hypokalemia resulting from diarrhea may intensify the risk of arrhythmia in co-administered patients.
Laxatives Restriction Concomitant intake should be avoided as it potentiates the adverse effect of loose stools and fluid imbalance.
Food Pharmacokinetic (Increased Exposure) Co-administration with a meal increases the overall bioavailability of the active substance by approximately 25%.
Alcohol Restriction Patients are advised to limit intake due to an officially documented enhanced risk of hepatic injury.

Population-Specific Notes

Official regulatory documents advise against the use of Ostirein in the elderly (65 years and above) because the increased risk of severe diarrhea heightens the significance of the pharmacodynamic interactions with Diuretics and Cardiac Glycosides. Additionally, a diagnosis of current or previous liver disease is a contraindication, which must be considered when co-administering other medicinal products associated with hepatic injury.

Mechanism of Action

Modulation of the Interleukin-1 mathbf(IL-1beta) Pathway

The mechanism centers on its active metabolite, Rhein, which acts by inhibiting the production and activity of the cytokine IL-1beta. This molecule mediates a pivotal inflammatory cascade in joint tissue. By downregulating IL-1beta signaling, the drug modulates a signaling cascade that drives structural change, which differs from pathways governing fast-onset peripheral pain.

Modulation of Catabolic Enzymes and Matrix Homeostasis

Blocking IL-1beta initiates a crucial mechanistic cascade: it suppresses the activation of the NF-kappaB transcription factor, which in turn reduces the gene expression of destructive enzymes like Matrix Metalloproteinases ( MMPs). This anti-catabolic action reduces the breakdown of the cartilage's structural components, such as collagen, thereby altering the net catabolic balance in the tissue.

Mechanism-Dependent Slow Kinetics

The physiological effect is fundamentally constrained by the requirement for the drug's inactive form, Diacerein, to be metabolized into the active Rhein, and by the time needed to cumulatively modulate the target cytokine and transcription factor pathways. This pathway-level adjustment relies on chronic exposure to the active metabolite, structurally defining the slow kinetics required to achieve significant pathway modulation.

Dosage and Administration Information

How to Use Ostirein: Official Administration Guidelines

The usage of Ostirein, which contains the active substance Diacerein, follows a two-phase oral dosing schedule. This medication is administered via the oral route as a 50 mg hard capsule and should be initiated by physicians experienced in treating osteoarthritis.


Standard Labeled Administration

Administration follows a structured two-part regimen for adult use:

  • Initial Phase: Treatment begins with a starting dose of 50 mg once daily (one capsule) for the first two to four weeks. This initial period is used to help the body adjust to the medication.
  • Maintenance Phase: The dose is subsequently increased to the standard maintenance level of 100 mg per day, administered as 50 mg twice daily (two capsules).

Essential Contextual Instructions

Ostirein capsules must be taken with food to ensure appropriate administration. For the maintenance regimen, this means taking one capsule with breakfast and the other with the evening meal. The capsule must be swallowed whole (intact) with a glass of water and should not be opened or crushed.


Population-Specific Dosing Rules

Specific adjustments are required for certain patient groups:

  • Severe Renal Impairment: For patients with severe kidney problems (creatinine clearance < 30 mL/min), the standard daily dose is halved to 50 mg once daily.
  • Older Adults (over 65 years): The use of this medication is not recommended in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

How Trials Were Conducted

Research examined the drug's effect in clinical trials. Clinical trials evaluated the use of the drug following the onset of a headache.


Efficacy Findings in Acute Attacks

In randomized controlled trials (RCTs), the drug was associated with outcomes such as freedom from pain at 2 hours. Research evaluated whether the drug was associated with a reduction in pain intensity.

The studies compared the 50 mg dose to the 25 mg dose, examining outcomes such as the percentage of participants reporting headache relief within 2 hours.

Study Dose Percentage Pain Free at 2 Hours Percentage Reporting Relief at 2 Hours
Study A 50 mg 58% Not reported
Study A 25 mg 43% Not reported
Study A Placebo 21% Not reported
Study B 50 mg Not reported 61%
Study B 25 mg Not reported 47%
Study B Placebo Not reported 25%

Study Details and Long-Term Evidence

Studies recorded adverse events among participants to establish the safety profile. The trials often excluded participants with certain pre-existing conditions.

Researchers have investigated whether use of the drug is associated with changes in long-term quality of life. Studies on the long-term use of the drug are ongoing, and evidence remains limited regarding effects beyond the acute treatment phase.

Frequently Asked Questions (FAQ)

Common questions about Ostirein (FAQ)

Q: What is the main difference between Ostirein and other similar treatments?

A: Official documents classify this medicine as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA). Its action is focused on modulating inflammatory pathways associated with joint damage. It is described as distinct from common analgesics because its role is not to provide immediate pain relief.

Q: Can I use Ostirein if I have a history of certain allergies?

A: Official product information lists hypersensitivity to the active substance, Diacerein, or its derivatives as a contraindication. If a history of this or other significant allergies exists, consultation with a healthcare professional before initiating treatment is required.

Q: Are there any specific foods or drinks I should avoid while taking Ostirein?

A: Regulatory sources advise that alcohol intake should be limited due to an officially documented enhanced risk of hepatic injury. Additionally, the medicine should not be taken at the same time as antacids. Official product information does not typically list restrictions for other specific foods or non-alcoholic drinks.

Q: How long does it usually take for Ostirein to start working?

A: Due to its slow-acting mechanism, the medicine is not intended to provide immediate symptom relief. Official literature indicates that beneficial changes may be observed after two to four weeks of treatment. The full therapeutic effect may require several weeks to a few months.

Q: Will Ostirein cause me to gain weight or feel tired?

A: Official safety summaries include reports of general side effects such as fatigue (tiredness) in some patients. Weight gain is not explicitly listed as a known side effect in the official product information.

Q: Is it normal to feel slightly nauseous when first starting Ostirein?

A: Official safety information lists nausea as a potential side effect. Gastrointestinal issues, including diarrhoea and abdominal pain, are categorized as very common and are often most noticeable when first starting treatment.

Q: How is Ostirein processed by the body?

A: This medicine is an inactive substance, known as a prodrug, which is fully converted into the active compound Rhein by the body. After this activation, the drug and its related compounds are primarily eliminated from the body via the kidneys (renal excretion).

Q: Does Ostirein interact with common over-the-counter pain relievers?

A: Official drug interaction information notes a potential increased risk of hepatic injury when combining Ostirein with Acetaminophen (paracetamol). Interactions with other nonsteroidal anti-inflammatory drugs (NSAIDs) have also been noted in regulatory documents.

Q: Can I take Ostirein if I'm already taking a supplement like magnesium or zinc?

A: Antacids, which contain minerals like magnesium, can significantly reduce the medicine's absorption. While general mineral supplements are not explicitly listed, it is generally advised that they be taken at least two hours apart from this medicine to prevent reduced systemic exposure.

Q: Were the studies on Ostirein short-term or long-term?

A: The efficacy trials used to establish approval focused on the acute treatment phase. Official literature notes that evidence for effects beyond the acute treatment phase is limited, though long-term safety evaluations have been conducted for treatment periods of up to 52 weeks.

Q: Why do some people on forums say they feel an effect immediately, but others don't?

A: The medicine is classified as a slow-acting agent and is not intended to provide immediate symptom relief, which explains the delayed effect. Its action relies on chronic exposure to the active substance to modulate inflammatory pathways within the joint tissue.

Q: What should I do if the side effects of Ostirein seem bothersome?

A: For general side effects that are bothersome, professional consultation is typically advised. For specific serious effects, such as unusually frequent, watery diarrhoea, the product information contains the instruction to stop taking the medicine immediately and contact a doctor.

Q: Does Ostirein affect mood or cause any mental health changes?

A: Official safety summaries list general nervous system effects such as dizziness and headache. There is no explicit mention of severe mood swings or psychiatric changes listed as known side effects in the core regulatory summary.

Q: Is there a maximum time someone is advised to take Ostirein?

A: The length of time for taking the drug is determined by a healthcare provider. In published clinical studies that assessed long-term safety, evaluations have been conducted for treatment periods of up to 52 weeks.

Q: Can I take Ostirein with a glass of milk?

A: The medicine must be taken with food to increase absorption. Because official instructions require separating the medicine from antacids, it is generally advised that the timing of administration be separated from large amounts of dairy/milk due to the risk of mineral content affecting absorption.

Q: What is the reason Ostirein is not recommended for people with heart conditions?

A: The medicine's most common side effect is severe diarrhoea, which may lead to low potassium levels (hypokalemia). This complication can increase the risk of serious side effects like arrhythmia when certain heart medications are taken concurrently.

Q: Are there any documented cases of addiction or dependence with Ostirein?

A: The medicine is not classified as a controlled substance (scheduled drug) in regulatory lists, which define drugs with potential for abuse or dependence. Official documents do not list dependence or withdrawal symptoms as known effects upon discontinuation.

Q: Does Ostirein contain gluten, lactose, or common allergens?

A: Official warnings advise informing a doctor about lactase deficiency because the medicine contains lactose. Complete information regarding other inactive ingredients (excipients) is provided in the full product information.

Q: What kind of monitoring (e.g., blood tests) is sometimes required while using Ostirein?

A: Regulatory restrictions stipulate that patient monitoring, particularly for signs of liver problems, is required. This process often involves routine blood tests, such as liver function tests, especially during the first few months of treatment.

Q: Why are pregnant women generally advised to avoid Ostirein?

A: Use is contraindicated (must not be used) during pregnancy. Official safety information indicates that studies have shown adverse effects on the fetus.

Q: Does taking Ostirein affect my ability to drive or operate machinery?

A: Official safety advice includes a caution about driving. Official safety advice recommends that driving occur only if the patient is alert, as general nervous system side effects like dizziness have been reported.

Q: Are there specific symptoms that warrant a doctor's attention while taking Ostirein?

A: Official patient information advises stopping the medicine immediately for unusually frequent, liquid, or watery stools. Attention should also be sought for symptoms that may indicate liver problems, such as jaundice, severe abdominal pain, or unexplained itching.

Q: How does the official literature describe the long-term safety profile of Ostirein?

A: The official literature states that evidence on long-term effects beyond the acute treatment phase is limited and ongoing. The safety profile is defined by the ongoing need to manage risks associated with liver injury and complications from severe diarrhoea.

Q: What happens if I accidentally take two doses of Ostirein close together?

A: Official warnings advise against taking more than the prescribed dose, as an overdose may occur and can lead to severe diarrhoea. Immediate contact with a doctor or poison control center is advised if this situation occurs.

How should Ostirein be stored and disposed of?

The official labeling for Ostirein (Diacerein) hard capsules strictly defines the required storage and disposal procedures to maintain product quality and safety.

Storage Scope Requirements (Regulatory Basis)
Temperature Store at 20 C to 25 C (68 F to 77 F) or not above 30 C.
Protection Keep in a dry place, protected from moisture and direct sunlight.
Handling Do not refrigerate or freeze the medicine.
Container Keep in the original container and ensure the container is tightly closed.
Disposal Do not release into the environment; disposal must not be via household trash or wastewater. Dispose of unused product according to local regulations for medicinal waste.
Child Safety Keep the medicine out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ostirein found in:

A-Z Index: